Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dy­nam­ics of the US pre­scrip­tion drug mar­ket were on full dis­play once again this morn­ing as Am­gen an­nounced that it would launch the first US biosim­i­lar for Hu­mi­ra, the best-sell­ing drug of all time, at two com­plete­ly dif­fer­ent list prices.

One price for Am­gen’s Am­je­vi­ta (adal­i­mum­ab-at­to) will be 55% be­low the cur­rent Hu­mi­ra list price, which is about $84,000 per year, and an­oth­er at a list price 5% be­low the cur­rent Hu­mi­ra list price, but pre­sum­ably (phar­ma com­pa­nies don’t dis­close re­bates) with high re­bates to at­tract PBMs and pay­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER